Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

Camilla Qvortrup; Benny Vittrup Jensen; Trine Lembrecht  Jørgensen; Dorte Nielsen; Jon Kroll Bjerregaard; Per Pfeiffer

doi:10.3109/0284186X.2010.482104

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

Camilla Qvortrup, Benny Vittrup Jensen, Trine Lembrecht Jørgensen, Dorte Nielsen, Jon Kroll Bjerregaard, Per Pfeiffer

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented.

Original language	English
Journal	Acta Oncologica
Volume	49
Issue number	6
Pages (from-to)	833-836
Number of pages	4
ISSN	0284-186X
DOIs	https://doi.org/10.3109/0284186X.2010.482104
Publication status	Published - 1. Aug 2010

Keywords

Administration, Oral
Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Camptothecin
Colorectal Neoplasms
Denmark
Drug Administration Schedule
Female
Humans
Indoles
Kaplan-Meier Estimate
Male
Middle Aged
Organoplatinum Compounds
Pyrroles
Receptor Protein-Tyrosine Kinases
Retrospective Studies
Treatment Outcome

Documents & Links

10.3109/0284186X.2010.482104

Fingerprint Dive into the research topics of 'Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this

@article{6222d82307aa4645aac5056aa837736c,

title = "Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer",

abstract = "Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented.",

keywords = "Administration, Oral, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colorectal Neoplasms, Denmark, Drug Administration Schedule, Female, Humans, Indoles, Kaplan-Meier Estimate, Male, Middle Aged, Organoplatinum Compounds, Pyrroles, Receptor Protein-Tyrosine Kinases, Retrospective Studies, Treatment Outcome",

author = "Camilla Qvortrup and Jensen, {Benny Vittrup} and J{\o}rgensen, {Trine Lembrecht} and Dorte Nielsen and Bjerregaard, {Jon Kroll} and Per Pfeiffer",

year = "2010",

month = aug,

day = "1",

doi = "10.3109/0284186X.2010.482104",

language = "English",

volume = "49",

pages = "833--836",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Taylor & Francis",

number = "6",

}

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. / Qvortrup, Camilla; Jensen, Benny Vittrup; Jørgensen, Trine Lembrecht ; Nielsen, Dorte; Bjerregaard, Jon Kroll; Pfeiffer, Per.

In: Acta Oncologica, Vol. 49, No. 6, 01.08.2010, p. 833-836.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

AU - Qvortrup, Camilla

AU - Jensen, Benny Vittrup

AU - Jørgensen, Trine Lembrecht

AU - Nielsen, Dorte

AU - Bjerregaard, Jon Kroll

AU - Pfeiffer, Per

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented.

AB - Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented.

KW - Administration, Oral

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Camptothecin

KW - Colorectal Neoplasms

KW - Denmark

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Indoles

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Organoplatinum Compounds

KW - Pyrroles

KW - Receptor Protein-Tyrosine Kinases

KW - Retrospective Studies

KW - Treatment Outcome

U2 - 10.3109/0284186X.2010.482104

DO - 10.3109/0284186X.2010.482104

M3 - Journal article

C2 - 20615171

VL - 49

SP - 833

EP - 836

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 6

ER -